Breaking Finance News

CONMED Corporation (NASDAQ:CNMD) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded CONMED Corporation (NASDAQ:CNMD) to Hold in a statement released on Tuesday September 27, 2016.

On 4/28/2016, Needham released a statement on CONMED Corporation (NASDAQ:CNMD) bumped up the target price from $48.00 to $49.00 that suggested an upside of 0.11%.

Boasting a price of $39.57, CONMED Corporation (NASDAQ:CNMD) traded 1.38% higher on the day. With the last close down -6.21% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. CONMED Corporation has recorded a 50-day average of $40.00 and a two hundred day average of $42.27. Volume of trade was down over the average, with 56,216 shares of CNMD changing hands under the typical 187,345

Performance Chart


With a total market value of $0, CONMED Corporation has price-earnings ratio of 64.04 with a one year low of $35.51 and a one year high of $51.90 .

A total of 5 analysts have released a research note on CNMD. Two analysts rating the company a strong buy, two analysts rating the company a buy, three analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $45.80.

More About CONMED Corporation (NASDAQ:CNMD)

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Its products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Its product lines consist of orthopedic surgery, general surgery and surgical visualization. Its orthopedic surgery product lines include sports medicine, powered surgical instruments, and sports biologics and tissue. Its general surgery product line offers a range of products in the areas of advanced surgical, endoscopic technologies and critical care. Its surgical visualization product line offers imaging systems for use in minimally invasive orthopedic and general surgery procedures. Its products are distributed domestically directly to over 6,000 hospitals and other healthcare institutions, as well as through medical specialty distributors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.